Cargando…

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment

Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decr...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Song Y, Green, Austin R, Hadi, Rouba, Doolittle-Amieva, Coley, Gardner, Jennifer, Moshiri, Ata S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/
https://www.ncbi.nlm.nih.gov/pubmed/36307152
http://dx.doi.org/10.1136/jitc-2022-005257
_version_ 1784821487039938560
author Park, Song Y
Green, Austin R
Hadi, Rouba
Doolittle-Amieva, Coley
Gardner, Jennifer
Moshiri, Ata S
author_facet Park, Song Y
Green, Austin R
Hadi, Rouba
Doolittle-Amieva, Coley
Gardner, Jennifer
Moshiri, Ata S
author_sort Park, Song Y
collection PubMed
description Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decrease of tumor size often occurs rapidly within the first 2–3 months, while improvement of the pigmentation takes several more months. Such clinical observation of lasting pigmentation could be explained by tumorous melanosis—a histopathological term referring to the presence of a melanophage-rich inflammatory infiltrate without remaining viable tumor cells. Herein, we report six patients with metastatic cutaneous melanoma who were treated with T-VEC. Biopsies were performed after observing clinical responses in the injected tumors. Pathological evaluation demonstrated non-viable or absent tumor tissue with tumorous melanosis in all cases. To accurately assess response to therapy and potentially decrease unnecessary additional T-VEC treatments, serial biopsy of ‘stable’ lesions should be considered to assess the presence or absence of viable tumor.
format Online
Article
Text
id pubmed-9621191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96211912022-11-01 Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment Park, Song Y Green, Austin R Hadi, Rouba Doolittle-Amieva, Coley Gardner, Jennifer Moshiri, Ata S J Immunother Cancer Case Report Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decrease of tumor size often occurs rapidly within the first 2–3 months, while improvement of the pigmentation takes several more months. Such clinical observation of lasting pigmentation could be explained by tumorous melanosis—a histopathological term referring to the presence of a melanophage-rich inflammatory infiltrate without remaining viable tumor cells. Herein, we report six patients with metastatic cutaneous melanoma who were treated with T-VEC. Biopsies were performed after observing clinical responses in the injected tumors. Pathological evaluation demonstrated non-viable or absent tumor tissue with tumorous melanosis in all cases. To accurately assess response to therapy and potentially decrease unnecessary additional T-VEC treatments, serial biopsy of ‘stable’ lesions should be considered to assess the presence or absence of viable tumor. BMJ Publishing Group 2022-10-28 /pmc/articles/PMC9621191/ /pubmed/36307152 http://dx.doi.org/10.1136/jitc-2022-005257 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Park, Song Y
Green, Austin R
Hadi, Rouba
Doolittle-Amieva, Coley
Gardner, Jennifer
Moshiri, Ata S
Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title_full Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title_fullStr Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title_full_unstemmed Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title_short Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
title_sort tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/
https://www.ncbi.nlm.nih.gov/pubmed/36307152
http://dx.doi.org/10.1136/jitc-2022-005257
work_keys_str_mv AT parksongy tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment
AT greenaustinr tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment
AT hadirouba tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment
AT doolittleamievacoley tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment
AT gardnerjennifer tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment
AT moshiriatas tumoralmelanosismimickingresidualmelanomainthesettingoftalimogenelaherparepvectreatment